Clinical trial
Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of…
NCT00164359 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00164359 |
|---|---|
| Title | Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi |
| Official title | A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Ministry of Health and Population, Malawi |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Malaria, Falciparum |
| Intervention type | Drug |
| Interventions | Amodiaquine plus artesunate, chlorproguanil-dapsone plus artesunate |
| Enrollment | 212 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Sep 27, 2012 |
| Countries | Malawi |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: